3
Clinical Trials associated with Cyanocobalamin/Folic acid/Pyridoxine hydrochlorideEffect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy
Homocysteine, a well-known inducer of vascular endothelial cell damage has been associated with extracellular matrix changes. Many studies demonstrated that high levels of this aminoacid in diabetic patients increases significantly the risk of the development of this pathology. This study has been undertaken to investigate the role of homocysteine and its cofactors (folic acid, vitamin B6 and B12) during the progression of the diabetic retinopathy.
Effect of Polyvitaminics (Pyridoxine Hydrochloride, Folic Acid and Cyanocobalamin) in the Concentration of Homocysteine and Lipid Profile in Postmenopausal Women: a Randomized Controlled, Double-blind Clinical Trial
Introduction: Cardiovascular diseases (CVD) are the main cause of death in Western countries. High levels of homocysteine (He) has been considered an important risk factor for coronary artery disease. Objective: To evaluate the effects of the drug Tenavit® (pyridoxine hydrochloride 4.00mg + folic acid 0.80mg + cyanocobalamin 0.40 mg) on plasma homocysteine concentrations and lipid profile in postmenopausal women. Methods: Sixty women were postmenopausal selected from the outpatient Gynecology Hospital Santa Marcelina that passed by routine consultations and fulfilling the inclusion criteria were invited to the study. The women were randomly allocated to control or experimental group (30 in each group) in a do uble-blind controlled clinical trial. The experimental group received one tablet of Tenavit® daily and the placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months. The women were assessed before the intervention and after 4 months of medication. A self-report questionnaire to assess quality of life (QSF-36) was applied and anthropometric measurements, cholesterol and fractions, triglycerides, fasting glucose, homocysteine and cysteine were evaluated. Results: The only variable that presented significant alteration in both dimensions (between and within group) was the homocysteine. It was observed statistical significant between groups in the final measure for homocysteine (control group: 11.5mmol/ L; experimental group: 9.4 mmo
CSP #453 - Homocysteinemia in Kidney and Endstage Renal Disease Study (HOST)
The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.
100 Clinical Results associated with Cyanocobalamin/Folic acid/Pyridoxine hydrochloride
100 Translational Medicine associated with Cyanocobalamin/Folic acid/Pyridoxine hydrochloride
100 Patents (Medical) associated with Cyanocobalamin/Folic acid/Pyridoxine hydrochloride
4
Literatures (Medical) associated with Cyanocobalamin/Folic acid/Pyridoxine hydrochloride17 May 2000·Lakartidningen
[TrioBe--the Medical Products Agency should re-evaluate the information text in the Fass!].
Letter
Author: Asplund, K ; Norberg, B
[What can we learn from the marketing of TrioBe?].
Letter
Author: Svensson, Staffen ; Mellén, Anders
[Non-reliable marketing of TrioBe].
Article
Author: Lindgren, Anders
100 Deals associated with Cyanocobalamin/Folic acid/Pyridoxine hydrochloride